Literature DB >> 29343576

Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.

Ruimin Pan1, Yali Qin2, Marisa Banasik2, William Lees3, Adrian J Shepherd3, Michael W Cho4, Xiang-Peng Kong5.   

Abstract

The third variable (V3) loop of HIV-1 gp120 is an immunodominant region targeted by neutralizing antibodies (nAbs). Despite limited breadth, better characterization of the structural details of the interactions between these nAbs and their target epitopes would enhance our understanding of the mechanism of neutralization and facilitate designing better immunogens to induce nAbs with greater breadth. Recently, we isolated two anti-V3 neutralizing monoclonal antibodies (MAbs), 10A3 and 10A37, from a rabbit immunized with gp120 of the M group consensus sequence. In this study, crystal structures of these MAbs bound to target epitopes were determined. 10A3 binds to the V3 crown (303TRKSIHIGPGRAF317) using the cradle binding mode, similar to human V3 MAbs encoded by IGHV5-51 germ line genes, and its epitope structure resembles that bound to the human antibodies. In contrast, 10A37, which exhibits greater breadth and potency than 10A3, binds the V3 crown and the succeeding stem region (308HIGPGRAFYTTGEI323). Unexpectedly, the 315RAFYTT320 portion of the epitope existed as helical turns, a V3 structure that has not been observed previously. Its main chain-dominated antigen-antibody interactions not only explain the broad neutralization of 10A37 but also show that its epitope is a potential vaccine target to be further evaluated. In conclusion, our study provides novel insights about neutralization-susceptible epitope structures of the V3 loop of HIV-1 gp120 and demonstrates that, despite low amino acid sequence similarity to human antibody germ line genes, rabbits can serve as a useful animal model to evaluate human vaccine candidates.IMPORTANCE The apex crown of V3 of HIV-1 gp120 is the most immunogenic region of the surface glycoprotein, and many MAbs targeting this region have been developed. Structural understanding of V3 crown MAbs not only can help understand how antibody responses target this unique region but also contribute to immunogen design for vaccine development. We present here crystal structures of two neutralizing V3 MAbs, 10A3 and 10A37, developed from a rabbit immunized with gp120. Our analysis of 10A3 in complex with V3 provided a detailed example of how epitope complexity can evolve with affinity maturation, while that of 10A37 revealed a novel V3 binding mode targeting the C-terminal side of the V3 crown and showed that this region can form a helical structure. Our study provides novel insights about neutralization-susceptible V3 epitope structures and demonstrates that rabbits can serve as a useful animal model to evaluate human vaccine candidates.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; V3; V3 loop; gp120; neutralizing antibody

Mesh:

Substances:

Year:  2018        PMID: 29343576      PMCID: PMC5972897          DOI: 10.1128/JVI.01894-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.

Authors:  L A Ivanoff; J W Dubay; J F Morris; S J Roberts; L Gutshall; E J Sternberg; E Hunter; T J Matthews; S R Petteway
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

Authors:  Christian H Bell; Ralph Pantophlet; André Schiefner; Lisa A Cavacini; Robyn L Stanfield; Dennis R Burton; Ian A Wilson
Journal:  J Mol Biol       Date:  2007-11-13       Impact factor: 5.469

3.  Characterization of HIV-1 neutralization escape mutants.

Authors:  J A McKeating; J Gow; J Goudsmit; L H Pearl; C Mulder; R A Weiss
Journal:  AIDS       Date:  1989-12       Impact factor: 4.177

4.  The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution.

Authors:  W F Vranken; M Budesinsky; F Fant; K Boulez; F A Borremans
Journal:  FEBS Lett       Date:  1995-10-23       Impact factor: 4.124

5.  A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.

Authors:  J D Laman; M M Schellekens; G K Lewis; J P Moore; T J Matthews; J P Langedijk; R H Meloen; W J Boersma; E Claassen
Journal:  AIDS Res Hum Retroviruses       Date:  1993-07       Impact factor: 2.205

6.  Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.

Authors:  G Zwart; H Langedijk; L van der Hoek; J J de Jong; T F Wolfs; C Ramautarsing; M Bakker; A de Ronde; J Goudsmit
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

7.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

8.  Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Authors:  Preetha Balasubramanian; Rajnish Kumar; Constance Williams; Vincenza Itri; Shixia Wang; Shan Lu; Ann J Hessell; Nancy L Haigwood; Faruk Sinangil; Keith W Higgins; Lily Liu; Liuzhe Li; Phillipe Nyambi; Miroslaw K Gorny; Maxim Totrov; Arthur Nadas; Xiang-Peng Kong; Susan Zolla-Pazner; Catarina E Hioe
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

9.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

10.  Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.

Authors:  Susan Zolla-Pazner; Paul T Edlefsen; Morgane Rolland; Xiang-Peng Kong; Allan deCamp; Raphael Gottardo; Constance Williams; Sodsai Tovanabutra; Sandra Sharpe-Cohen; James I Mullins; Mark S deSouza; Nicos Karasavvas; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Punnee Pitisuttihum; Jaranit Kaewkungwal; Robert J O'Connell; Merlin L Robb; Nelson L Michael; Jerome H Kim; Peter Gilbert
Journal:  EBioMedicine       Date:  2014-11-01       Impact factor: 8.143

View more
  3 in total

1.  Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants.

Authors:  Tatsuhiko Ozawa; Hideki Tani; Yuki Anraku; Shunsuke Kita; Emiko Igarashi; Yumiko Saga; Noriko Inasaki; Hitoshi Kawasuji; Hiroshi Yamada; So-Ichiro Sasaki; Mayu Somekawa; Jiei Sasaki; Yoshihiro Hayakawa; Yoshihiro Yamamoto; Yoshitomo Morinaga; Nobuyuki Kurosawa; Masaharu Isobe; Hideo Fukuhara; Katsumi Maenaka; Takao Hashiguchi; Hiroyuki Kishi; Isao Kitajima; Shigeru Saito; Hideki Niimi
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

2.  Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization.

Authors:  Nikolas Friedrich; Emanuel Stiegeler; Matthias Glögl; Thomas Lemmin; Simon Hansen; Claus Kadelka; Yufan Wu; Patrick Ernst; Liridona Maliqi; Caio Foulkes; Mylène Morin; Mustafa Eroglu; Thomas Liechti; Branislav Ivan; Thomas Reinberg; Jonas V Schaefer; Umut Karakus; Stephan Ursprung; Axel Mann; Peter Rusert; Roger D Kouyos; John A Robinson; Huldrych F Günthard; Andreas Plückthun; Alexandra Trkola
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

3.  A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion.

Authors:  Taha Azad; Reza Rezaei; Ragunath Singaravelu; Taylor R Jamieson; Mathieu J F Crupi; Abera Surendran; Joanna Poutou; Parisa Taklifi; Juthaporn Cowan; Donald William Cameron; Carolina S Ilkow
Journal:  Nanomaterials (Basel)       Date:  2021-03-22       Impact factor: 5.076

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.